Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Physiology - Gastrointestinal and Liver Physiology

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/AJPGI.00360.2002PMID 12631557
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.

  2002cited by this paper
• Strategies to manage the adverse effects of oral morphine: an evidence-based report.

  2001influential reference
• Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans.

  2001cited by this paper
• Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans.

  2001cited by this paper
• Differential Effects of μ-, δ-, and κ-Opioid Receptor Agonists on Mechanosensitive Gastric Vagal Afferent Fibers in the Rat

  2000cited by this paper
• Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat.

  2000cited by this paper
• Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat.

  2000cited by this paper
• Effects of a serotonin 5-HT4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans

  2000cited by this paper
• Effect of opioid active therapeutics on the ascending reflex pathway in the rat ileum.

  2000cited by this paper
• Effects of macronutrient content and energy density of snacks consumed in a satiety state on the onset of the next meal.

  2000cited by this paper
• Functional bowel disorders and functional abdominal pain

  1999cited by this paper
• Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans.

  1999cited by this paper
• Effects of kappa opioids in the inflamed rat colon.

  1999cited by this paper
• The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

  1999cited by this paper
• The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome.

  1999cited by this paper
• Characteristics of dependent and nondependent regular users of codeine.

  1999cited by this paper
• Rectal tone, distensibility, and perception: reproducibility and response to different distensions.

  1998cited by this paper
• Rectal tone, distensibility, and perception: reproducibility and response to different distensions.

  1998cited by this paper
• Brain concentrations of asimadoline in mice: the influence of coadministration of various P-glycoprotein substrates.

  1998cited by this paper
• Two-lumen tubing is required for accurate barostat studies

  1998cited by this paper
• Role of impaired gastric accommodation to a meal in functional dyspepsia.

  1998cited by this paper
• Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation.

  1998cited by this paper
• Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect.

  1997cited by this paper
• Spinally administered dynorphin A produces long‐lasting allodynia: involvement of NMDA but not opioid receptors

  1997cited by this paper
• Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets.

  1997cited by this paper
• Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia

  1997cited by this paper
• Adrenergic modulation of human colonic motor and sensory function.

  1997cited by this paper
• Adrenergic modulation of human colonic motor and sensory function.

  1997cited by this paper
• Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans

  1996cited by this paper
• Central administration of beta-endorphin increases food intake in goldfish: pretreatment with the opioid antagonist naloxone.

  1995cited by this paper
• Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon.

  1995cited by this paper
• The control of pain in peripheral tissue by opioids.

  1995cited by this paper
• Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome

  1995cited by this paper
• kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system.

  1995cited by this paper
• Contrasting Actions of Intrathecal U50, 488H, Morphine, or [D-Pen sup 2, D-Pen sup 5] Enkephalin or Intravenous U50, 488H on the Visceromotor Response to Colorectal Distension in the Rat

  1995cited by this paper
• Spinal mu and delta, but not kappa, opioid‐receptor agonists attenuate responses to noxious colorectal distension in the rat

  1995cited by this paper
• Molecular pharmacology of the opioid receptors.

  1995cited by this paper
• K-OPIOID ACTIVITY OF THE FOUR STEREOISOMERS OF THE PERIPHERALLY SELECTIVE -AGONISTS, EMD 60 400 AND EMD 61 753

  1994cited by this paper
• kappa-Opioid activity of the four stereoisomers of the peripherally selective kappa-agonists, EMD 60,400 and EMD 61,753.

  1994cited by this paper
• A pharmacological profile of the novel, peripherally‐selective k‐opioid receptor agonist, EMD 61753

  1994cited by this paper
• Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat.

  1994cited by this paper
• Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome.

  1994cited by this paper
• Sensory innervation of the viscera: peripheral basis of visceral pain.

  1994cited by this paper
• Antagonistic effects of the selective, competitive N-methyl-D-aspartate (NMDA) receptor antagonist, NPC 12626, on kappa opiate-induced analgesia in male deer mice.

  1994cited by this paper
• Peripheral κ-opioid receptors mediate the antinociceptive effect of fetodozine on the duodenal pain reflex in rat

  1994cited by this paper
• Characterization of mechanosensitive pelvic nerve afferent fibers innervating the colon of the rat.

  1994cited by this paper
• U. S. Householder survey of functional gastrointestinal disorders

  1993cited by this paper
• Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.

  1993cited by this paper
• The specific N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 blocks U-50,488, but not morphine antinociception.

  1992cited by this paper
• Morphine- and naltrexone-induced modification of palatability: analysis by the taste reactivity test.

  1992cited by this paper
• Variation of muscle tone in the human colon.

  1991cited by this paper
• Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons.

  1990cited by this paper
• A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus

  1990cited by this paper
• Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture.

  1989cited by this paper
• Human gastric emptying and colonic filling of solids characterized by a new method.

  1989cited by this paper
• Inhibitor of cyclic AMP-dependent protein kinase blocks opioid-induced prolongation of the action potential of mouse sensory ganglion neurons in dissociated cell cultures.

  1988cited by this paper
• Role of opiate receptors in the regulation of colonic transit.

  1988cited by this paper
• Scintigraphic determination of the effect of metoclopramide and morphine on small intestinal transit time.

  1988cited by this paper
• Characterization of neurons responsive to noxious colorectal distension in the T13-L2 spinal cord of the rat.

  1988cited by this paper
• Maturation of opioid sensitivity of fetal mouse dorsal root ganglion neuron perikarya in organotypic cultures: regulation by spinal cord.

  1986cited by this paper
• Dynorphin and neoendorphin peptides decrease dorsal root ganglion neuron calcium-dependent action potential duration.

  1985cited by this paper
• Dual action of naloxone on feeding revealed by behavioural analysis: separate effects on initiation and termination of eating.

  1984cited by this paper
• MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES: EVIDENCE THAT MORPHÌNE DECREASES TONIC DESCENDING INHIBITION IN THE ANAESTHETIZED CAT

  1980cited by this paper
• Enkephalin inhibits release of substance P from sensory neurons in culture and decreases action potential duration.

  1979cited by this paper

• Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract

  2025cites this paper
• The impact of transcutaneous electrical acustimulation (TEA) on rectal distension‐induced pain in patients with irritable bowel syndrome (IBS)—A study to determine the optimal TEA delivery modalities and effects on rectal sensation and autonomic function

  2024cites this paper
• Coexpressed δ-, μ-, and κ-Opioid Receptors Modulate Voltage-Gated Ca2+ Channels in Gastric-Projecting Vagal Afferent Neurons

  2024cites this paper
• Efficacy of opioid receptor modulators in patients with irritable bowel syndrome

  2021cites this paper
• Association between opioid usage and rectal dysfunction in constipation: A cross‐sectional study of 2754 patients

  2020cites this paper
• Advances in Achieving Opioid Analgesia Without Side Effects

  2018cites this paper
• Contribution of membrane receptor signalling to chronic visceral pain.

  2018cites this paper
• Regional Colonic Transit Pattern Does Not Conclusively Identify Evacuation Disorders in Constipated Patients with Delayed Colonic Transit

  2017cites this paper
• Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral hypersensitivity

  2017cites this paper
• Examining the acute effects of exercise intensity on subsequent appetite, food intake, resting energy expenditure and fat oxidation.

  2016cites this paper
• 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.

  2016cites this paper
• Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design

  2016cites this paper
• Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications.

  2016cites this paper
• Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial

  2016cites this paper
• Current and Emerging Medical Therapies for Gastroparesis

  2015cites this paper
• Optimisation of in silico derived 2-aminobenzimidazole hits as unprecedented selective kappa opioid receptor agonists.

  2015cites this paper
• Drug discovery approaches to irritable bowel syndrome

  2015cites this paper
• Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.

  2014cites this paper
• 16. Terapias futuras

  2014cites this paper
• Novel Orally Available Salvinorin A Analog PR-38 Inhibits Gastrointestinal Motility and Reduces Abdominal Pain in Mouse Models Mimicking Irritable Bowel Syndrome

  2014cites this paper
• HUMAN VISCERAL AFFERENT RECORDINGS: A PRE-CLINICAL HUMAN MODEL OF VISCERAL PAIN.

  2014cites this paper
• The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review

  2013cites this paper
• Increased κ-opioid receptor expression and function during chronic visceral hypersensitivity

  2013cites this paper
• Simplifying the measurement of gastric accommodation using SPECT

  2013cites this paper
• Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives

  2013cites this paper
• Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.

  2013cites this paper
• Peripherally Restricted Opioid Analgesics

  2013cites this paper
• Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

  2013cites this paper
• Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives

  2012cites this paper
• Brain-Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders

  2012cites this paper
• Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review

  2012cites this paper
• Neurophysiologic Mechanisms of Human Large Intestinal Motility

  2012cites this paper
• Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome

  2012cites this paper
• Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants

  2012cites this paper
• Tratamiento farmacológico del dolor abdominal visceral crónico: Evaluación crítica de la evidencia disponible

  2011cites this paper
• Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

  2011cites this paper
• Potential biomarkers.

  2011cites this paper
• Peripheral opioid receptor agonists for analgesia: a comprehensive review.

  2011cites this paper
• Dyspepsia and Appetite Regulation

  2011cites this paper
• Review article: the role of gastric motility in the control of food intake

  2011cites this paper
• Review article: new receptor targets for medical therapy in irritable bowel syndrome

  2010cites this paper
• Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment.

  2010cites this paper
• Emerging Pharmacologic Therapies for Irritable Bowel Syndrome

  2010cites this paper
• Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions

  2010cites this paper
• Gastrointestinal targets of appetite regulation in humans

  2010cites this paper
• Reproducibility and Performance Characteristics of Colonic Compliance, Tone, and Sensory Tests in Healthy Humans

  2010cites this paper
• Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort

  2010cites this paper
• Kappa opioids and the modulation of pain

  2010cites this paper
• Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.

  2009cites this paper
• Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ‐opioid and cannabinoid receptors

  2009cites this paper
• Effect of a κ‐opioid agonist, i.v. JNJ‐38488502, on sensation of colonic distensions in healthy male volunteers

  2009cites this paper
• Controlled trial of hypnotherapy as a treatment for irritable bowel syndrome.

  2009cites this paper
• Influence of naloxone on rectal sensorimotor function in health

  2009cites this paper
• High body mass alters colonic sensory-motor function and transit in humans.

  2008cites this paper
• Updates on treatment of irritable bowel syndrome.

  2008cites this paper
• Asimadoline in the treatment of irritable bowel syndrome

  2008cites this paper
• Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome.

  2008cites this paper
• Novel pharmacology: asimadoline, a κ‐opioid agonist, and visceral sensation

  2008cites this paper
• Role of endogenous opioids in the control of gastric sensorimotor function

  2008cites this paper
• Asimadoline, a kappa‐opioid agonist, and satiation in functional dyspepsia

  2008cites this paper
• A review of irritable bowel syndrome and an update on therapeutic approaches

  2008cites this paper
• PATHOPHYSIOLOGICAL FACTORS OF IRRITABLE BOWEL SYNDROME, AND THE EFFECTS OF PROBIOTIC SUPPLEMENTATION

  2008cites this paper
• Satiety testing: ready for the clinic?

  2008cites this paper
• The Role of the Gastrointestinal Tract in Satiation, Satiety, and Food Intake: Evidence from Research in Humans

  2008cites this paper
• Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists

  2008cites this paper
• Prospective Study of Motor, Sensory, Psychological and Autonomic Functions in Patients with Irritable Bowel Syndrome

  2008cites this paper
• Treatment of opioid-induced gut dysfunction

  2007cites this paper
• Novel therapeutic targets for enteric nervous system disorders.

  2007cites this paper
• Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome.

  2007cites this paper
• 6.29 – Irritable Bowel Syndrome

  2007cites this paper
• Differential effect of opioids in patients with chronic pancreatitis: An experimental pain study

  2007cites this paper
• Effects of opioid subtypes on detrusor overactivity in rats with cerebral infarction

  2007cites this paper
• Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans

  2007cites this paper
• Current gut-directed therapies for irritable bowel syndrome

  2006cites this paper
• Management of Visceral Pain Due to Cancer-Related Intestinal Obstruction

  2006cites this paper
• IBS--review and what's new.

  2006cites this paper
• Irritable bowel syndrome and chronic constipation: Emerging drugs, devices, and surgical treatments

  2006cites this paper
• Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women

  2006cites this paper
• Irritable bowel syndrome: Update on colonic neuromuscular dysfunction and treatment

  2006cites this paper
• Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders.

  2006cites this paper
• Peripheral Opioids for Functional GI Disease: A Reappraisal

  2006cites this paper
• Challenges in drug development for functional gastrointestinal disorders. Part II: Visceral pain

  2006cites this paper
• Treatments targeting putative mechanisms in irritable bowel syndrome

  2005cites this paper
• Alvimopan, a selective peripherally acting μ‐opioid antagonist *

  2005cites this paper
• Frontiers in functional dyspepsia

  2005cites this paper
• New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments

  2005cites this paper
• Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study.

  2005cites this paper
• Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility

  2005cites this paper
• Gastric motor and sensory functions in obesity.

  2005cites this paper
• Advances in Pharmacological Treatments of IBS

  2004cites this paper
• Functional dyspepsia: drugs for new (and old) therapeutic targets.

  2004cites this paper
• PII: S1542-3565(04)00454-9

  2004cites this paper
• A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia.

  2004cites this paper
• Opioids and the gut: pharmacology and current clinical experience

  2004cites this paper
• Preclinical studies of opioids and opioid antagonists on gastrointestinal function

  2004cites this paper
• Independent influences of body mass and gastric volumes on satiation in humans.

  2004cites this paper
• Treatment of functional dyspepsia

  2004cites this paper
• Posibilidades farmacológicas de modulación de la percepción visceral

  2004cites this paper
• Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

  2004cites this paper
• Treatment of Functional

  2004cites this paper